Overview

Tofacitinib in Depression (TIDE)

Status:
Suspended

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

This study will test whether 7-10 day administration of the anti-inflammatory drug, tofacitinib, has positive effects on people experiencing treatment-resistant depression compared to placebo.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Oxford

Collaborators:

Medical Research Council
Wellcome Trust

Treatments:

Tofacitinib